Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study | Synapse
March 3, 2026Open Access
Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study
Key Points
Improved survival rates were observed with immune checkpoint inhibitor rechallenge in nasopharyngeal carcinoma patients.
The prognostic model accurately stratified patients, predicting outcomes based on their response to previous treatments.
Real-world data collection provided insights into the effectiveness of immune checkpoint inhibitors in recurrent disease.
Findings suggest that rechallenging patients may enhance overall treatment strategies for aggressive nasopharyngeal carcinoma.